Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To obtain further information on the tolerability of Atrovent® inhalets in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Ipratropium

Criteria

Inclusion Criteria:

• Primarily, Patients with chronic obstructive airways disease

• Only patients who had not been treated with Atrovent® in the last year were to be considered for inclusion

Exclusion Criteria:

• Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® inhalets